ReviewAAPS PharmSciTech2019
Nanoparticles: Oral Delivery for Protein and Peptide Drugs.
Review in AAPS PharmSciTech, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 296 citations in OpenAlex.
- Emerging Technologies for Oral Peptide Delivery: From Bioinspired Systems to Smart Device-Assisted Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Phosphate-Surface-Modified Silica Nanoparticles for 5-Fluorouracil as a Prolonged Drug Delivery System.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Enhancement of the Physicochemical Properties of Brazilian Red Propolis Using Gelucire-Based Microencapsulation.ACS omega · 2026Article
- Tunneling Nanotubes in Astrocyte-Neuron Crosstalk: From Intercellular Communication and Pathological Spread to Mechanobiological and Bio-Inspired Approaches.Brain sciences · 2026Review
- Surface-Engineered Breviscapine Nanocrystals for Enhanced Oral Absorption and Cardioprotection in Isoprenaline-Induced Myocardial Infarction.International journal of nanomedicine · 2026Article
- Development of an Advanced Drug Delivery System for Protein- and Peptide-Based Therapeutics.Current pharmaceutical design · 2026Review
- Co-assembling de novo designed peptide with high-payload drug protein for noninvasive treatment of corneal neovascularization.International journal of pharmaceutics: X · 2025Article
- Engineering non-pathogenic bacteria for auto-transporter-driven secretion of functional interferon.Gut microbes · 2025Article
- Probiotic-based oral vaccine mucosal delivery system enabling genetically encoded dual-antigen arrays.Nature communications · 2025Article
- Nose-to-Brain Delivery of Acyl-Ghrelin Peptide Gold Nanoconjugates for Treatment of Neurodegenerative Diseases.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Breaking the oncogenic alliance: advances in disrupting the MTDH-SND1 complex for cancer therapy.RSC advances · 2025Review
- Enzyme Encapsulation in Liposomes: Recent Advancements in the Pharmaceutical and Food Sector.Nanomaterials (Basel, Switzerland) · 2025Review
- "Therapies Through Gut:" Targeted Drug Delivery for Non-Gastrointestinal Diseases by Oral Administration.Advanced healthcare materials · 2025Review
- Microneedle Innovations in Oral Therapeutics: Transforming Protein and Peptide Delivery.AAPS PharmSciTech · 2025Review
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- ShK-modified UCMSCs Inhibit M1-Like Macrophage Polarization and Alleviate Osteoarthritis Progression via PI3K/Akt Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Microneedle Technology for Overcoming Biological Barriers: Advancing Biomacromolecular Delivery and Therapeutic Applications in Major Diseases.Research (Washington, D.C.) · 2025Review
- Targeting Invasion: The Role of MMP-2 and MMP-9 Inhibition in Colorectal Cancer Therapy.Biomolecules · 2024Review
- Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation.Acta pharmaceutica Sinica. B · 2024Review
- Mucus-penetrating and permeation enhancer albumin-based nanoparticles for oral delivery of macromolecules: Application to bevacizumab.Drug delivery and translational research · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein and peptide drugs have many advantages, such as high bioactivity and specificity, strong solubility, and low toxicity. Therefore, the strategies for improving the bioavailability of protein peptides are reviewed, including chemical modification of nanocarriers, absorption enhancers, and mucous adhesion systems. The status, advantages, and disadvantages of various strategies are systematically analyzed. The systematic and personalized design of various factors affecting the release and absorption of drugs based on nanoparticles is pointed out. It is expected to design a protein peptide oral delivery system that can be applied in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.